Industry leaders offer reflections on 2022 and predictions for 2023
The COVID-19 pandemic has continued to evolve, forcing companies to adapt to a constantly changing landscape filled with fluid consumer expectations. Meanwhile, several other key healthcare-related trends have bubbled to the surface over that period.
What can we expect in pharma in 2023?
Drug pricing, CMS getting negotiating power for drug purchasing, vaccines, clinical trials, artificial intelligence, and Pharmacists becoming care givers. These are the highlights of 2022, what do the experts say we will see in 2023? We rounded up some experts and asked them just that. And join us for the next few weeks as we look at what we might see in 2023.
The 2023 PharmaVoice crystal ball: peering into the future of life sciences
For the 2023 PharmaVoice Year in Preview, we zeroed in on six key trends: clinical trial diversity, disruptive tech, innovation, talent management, patient engagement and leading through uncertain times. Here, we’ve asked industry execs to look into their crystal balls and tell us about anything they see coming.
Citeline and Norstella complete merger to form a $5 billion global pharmaceutical technology company
Nov. 1, 2022 – Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline (formerly Pharma Intelligence), a leader in the clinical trial intelligence space.
At deal close, the $5 billion global company is now one of the world’s largest pharma intelligence solutions providers on the market, with more than 1,600 employees across the five brands that make up Norstella: Evaluate, MMIT, Panalgo, The Dedham Group, and now Citeline.
Citeline and Norstella unite to offer life sciences clients a full suite of commercial and clinical solutions
June 28, 2022 – Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies.
MMIT announces winners of the Q1 2022 Patient Access Awards
June 23, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has launched the inaugural Patient Access Awards to honor pharmaceutical manufacturers committed to improving patient access to life-saving therapies.
Merger creates $5 billion pharma technology company
Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market.
Norstella, Citeline merge to create $5bn pharma tech firm
Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category.
Norstella completes acquisition of Citeline to form $5B pharma intelligence group
Although financial terms weren’t disclosed, Norstella estimates that it is now a $5 billion player in the market, the company said in a Nov. 1 press release. The acquisition was first announced in June.
Norstella completes merger with Citeline to form $5B pharma tech company
The combined company has more than 1,500 employees worldwide, including about 200 in the Philadelphia region.